Swiss pharmaceutical giant Novartis (NYSE: NVS) has officially launched its cholesterol-lowering drug, Leqvio (inclisiran), in China, priced at RMB 9,988 (approximately USD 1,367) per injection. Each pre-filled syringe contains 1.5ml with an effective content of 284mg. The drug is recommended for subcutaneous administration, with a second dose administered three months after the first, followed by one injection every six months. This regimen allows for a maintenance period requiring only two doses per year.
Innovative Mechanism of Action
Inclisiran is notable for being the world’s first and currently only small interfering RNA (siRNA) drug designed to lower LDL cholesterol (LDL-C) levels. It works by blocking the synthesis of PCSK9, a protein that leads to increased LDL-C levels, thereby providing a stable long-term reduction in LDL-C.
Global Approval Timeline
Leqvio was first approved in Europe for the treatment of hypercholesterolemia and mixed dyslipidemia in December 2020. The drug subsequently received market authorization in the United States in December 2021, with its indication expanded to include primary hyperlipidemia in July 2023. The launch in China marks a significant step in Novartis’ global strategy to address cholesterol management.-Fineline Info & Tech
